Logo image of STRO

SUTRO BIOPHARMA INC (STRO) Stock Fundamental Analysis

NASDAQ:STRO - Nasdaq - US8693671021 - Common Stock - Currency: USD

0.813  -0.01 (-1.7%)

After market: 0.825 +0.01 (+1.48%)

Fundamental Rating

1

STRO gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 551 industry peers in the Biotechnology industry. STRO has a bad profitability rating. Also its financial health evaluation is rather negative. STRO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year STRO has reported negative net income.
In the past year STRO has reported a negative cash flow from operations.
In the past 5 years STRO always reported negative net income.
STRO had negative operating cash flow in 4 of the past 5 years.
STRO Yearly Net Income VS EBIT VS OCF VS FCFSTRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

With a Return On Assets value of -76.29%, STRO is not doing good in the industry: 67.88% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -76.29%
ROE N/A
ROIC N/A
ROA(3y)-36.91%
ROA(5y)-29.96%
ROE(3y)-212.09%
ROE(5y)-137.55%
ROIC(3y)N/A
ROIC(5y)N/A
STRO Yearly ROA, ROE, ROICSTRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

STRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STRO Yearly Profit, Operating, Gross MarginsSTRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

STRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
STRO has more shares outstanding than it did 1 year ago.
STRO has more shares outstanding than it did 5 years ago.
STRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
STRO Yearly Shares OutstandingSTRO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
STRO Yearly Total Debt VS Total AssetsSTRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -5.21, we must say that STRO is in the distress zone and has some risk of bankruptcy.
STRO has a worse Altman-Z score (-5.21) than 61.34% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.21
ROIC/WACCN/A
WACC11.05%
STRO Yearly LT Debt VS Equity VS FCFSTRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

STRO has a Current Ratio of 2.16. This indicates that STRO is financially healthy and has no problem in meeting its short term obligations.
STRO has a Current ratio of 2.16. This is in the lower half of the industry: STRO underperforms 74.05% of its industry peers.
A Quick Ratio of 2.16 indicates that STRO has no problem at all paying its short term obligations.
STRO has a worse Quick ratio (2.16) than 71.87% of its industry peers.
Industry RankSector Rank
Current Ratio 2.16
Quick Ratio 2.16
STRO Yearly Current Assets VS Current LiabilitesSTRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

STRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -58.51%.
STRO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -56.88%.
The Revenue has been growing slightly by 7.74% on average over the past years.
EPS 1Y (TTM)-58.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.21%
Revenue 1Y (TTM)-56.88%
Revenue growth 3Y0.09%
Revenue growth 5Y7.74%
Sales Q2Q%33.76%

3.2 Future

STRO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.52% yearly.
The Revenue is expected to decrease by -1.83% on average over the next years.
EPS Next Y33.66%
EPS Next 2Y24.94%
EPS Next 3Y13.98%
EPS Next 5Y14.52%
Revenue Next Year-1.04%
Revenue Next 2Y-12.85%
Revenue Next 3Y-8.49%
Revenue Next 5Y-1.83%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
STRO Yearly Revenue VS EstimatesSTRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
STRO Yearly EPS VS EstimatesSTRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for STRO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STRO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STRO Price Earnings VS Forward Price EarningsSTRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STRO Per share dataSTRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as STRO's earnings are expected to grow with 13.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.94%
EPS Next 3Y13.98%

More info and screens

0

5. Dividend

5.1 Amount

STRO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SUTRO BIOPHARMA INC

NASDAQ:STRO (8/5/2025, 8:00:00 PM)

After market: 0.825 +0.01 (+1.48%)

0.813

-0.01 (-1.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-07 2025-08-07/amc
Inst Owners70.88%
Inst Owner Change0.03%
Ins Owners0.69%
Ins Owner Change6.28%
Market Cap68.67M
Analysts74.12
Price Target3.32 (308.36%)
Short Float %4.54%
Short Ratio3.8
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.54%
Min EPS beat(2)-26.1%
Max EPS beat(2)-4.99%
EPS beat(4)2
Avg EPS beat(4)4.29%
Min EPS beat(4)-26.1%
Max EPS beat(4)26.97%
EPS beat(8)4
Avg EPS beat(8)23.06%
EPS beat(12)5
Avg EPS beat(12)17.38%
EPS beat(16)6
Avg EPS beat(16)15.62%
Revenue beat(2)2
Avg Revenue beat(2)31.83%
Min Revenue beat(2)16.74%
Max Revenue beat(2)46.91%
Revenue beat(4)3
Avg Revenue beat(4)9.58%
Min Revenue beat(4)-45.24%
Max Revenue beat(4)46.91%
Revenue beat(8)6
Avg Revenue beat(8)112.14%
Revenue beat(12)9
Avg Revenue beat(12)85.55%
Revenue beat(16)10
Avg Revenue beat(16)67.45%
PT rev (1m)0%
PT rev (3m)-23.36%
EPS NQ rev (1m)4.66%
EPS NQ rev (3m)33.65%
EPS NY rev (1m)-4.77%
EPS NY rev (3m)10.67%
Revenue NQ rev (1m)-0.68%
Revenue NQ rev (3m)23.51%
Revenue NY rev (1m)-0.77%
Revenue NY rev (3m)23.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.03
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.98
EYN/A
EPS(NY)-1.33
Fwd EYN/A
FCF(TTM)-2.35
FCFYN/A
OCF(TTM)-2.31
OCFYN/A
SpS0.79
BVpS-0.31
TBVpS-0.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -76.29%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.91%
ROA(5y)-29.96%
ROE(3y)-212.09%
ROE(5y)-137.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 52%
Cap/Sales 5.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.16
Quick Ratio 2.16
Altman-Z -5.21
F-Score2
WACC11.05%
ROIC/WACCN/A
Cap/Depr(3y)81.45%
Cap/Depr(5y)145.34%
Cap/Sales(3y)6.47%
Cap/Sales(5y)12.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.21%
EPS Next Y33.66%
EPS Next 2Y24.94%
EPS Next 3Y13.98%
EPS Next 5Y14.52%
Revenue 1Y (TTM)-56.88%
Revenue growth 3Y0.09%
Revenue growth 5Y7.74%
Sales Q2Q%33.76%
Revenue Next Year-1.04%
Revenue Next 2Y-12.85%
Revenue Next 3Y-8.49%
Revenue Next 5Y-1.83%
EBIT growth 1Y-121.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.12%
EBIT Next 3Y17.09%
EBIT Next 5YN/A
FCF growth 1Y-574.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-777.74%
OCF growth 3YN/A
OCF growth 5YN/A